Wordt geladen...
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
BACKGROUND: Therapeutic advances have greatly extended survival times in patients with multiple myeloma, necessitating increasingly lengthy trials when using survival outcomes primary endpoints. A surrogate endpoint that can more rapidly predict survival could accelerate drug development. We conduct...
Bewaard in:
| Gepubliceerd in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444731/ https://ncbi.nlm.nih.gov/pubmed/31780415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2019.09.622 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|